Johnson & Johnson says long-term results for its ICOTYDE® (icotrokinra) treatment show sustained effectiveness and a continued favorable safety profile in people with plaque psoriasis. The company highlights new two-year data from a phase 3 program.
Across outlets, the reported findings focus on response durability in both adults and adolescents. PR Newswire states that data presented at a Fall Clinical Dermatology meeting show high, sustained response rates, including that nearly three-quarters of participants achieve clear or almost clear skin at two years. Seeking Alpha similarly frames the update as long-term data supporting ICOTYDE’s performance in plaque psoriasis, emphasizing the robustness of the longer follow-up.
The sources present the update primarily as an evidence and outcomes announcement tied to the clinical meeting, with emphasis on efficacy over an extended period and safety remaining consistent over time. However, the provided excerpts do not include detailed comparative results versus other therapies or the full study design. The reports therefore center on the headline two-year outcomes and their implication for durability of response in plaque psoriasis populations.
